Selskabets formål er indkøbe, produktion, ompakning og distribution af lægemidler og lignende produkter i Europa
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 10.5 mia. | 269.4 mio. | 2.7 mia. | 1.2 mia. | 144 | |
CVR: 17153684
Secondary names: MEDIPACK A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Nicki Lund Kristensen joined the board
The financial health of ORIFARM SUPPLY A/S appears robust, with a significant upward trajectory in both revenue and profit over the past few years. In 2024, the company reported revenue of 10.46 billion DKK and a profit of 269.4 million DKK, marking a notable increase from 8.75 billion DKK in revenue and 217.5 million DKK in profit in 2023. Equity has also strengthened, rising to 1.18 billion DKK, indicating a solid foundation for future growth. While the profit margins are improving, the company should remain vigilant about maintaining operational efficiency as it scales within the competitive pharmaceutical wholesale industry. Overall, ORIFARM SUPPLY A/S is positioned favorably, reflecting a strong growth trajectory and increasing market presence.
AI-generated summary
Companies in the same industry and area
companydata.dk